Skip to main content
OSTI.GOVU.S. Department of Energy Office of Scientific and Technical Information
U.S. Department of Energy
Office of Scientific and Technical Information
 

Predictive and therapeutic markers in ovarian cancer

Patent ·
OSTI ID:1082960
; ; ; ;
Cancer markers may be developed to detect diseases characterized by increased expression of apoptosis-suppressing genes, such as aggressive cancers. Genes in the human chromosomal regions, 8q24, 11q13, 20q11-q13, were found to be amplified indicating in vivo drug resistance in diseases such as ovarian cancer. Diagnosis and assessment of amplification levels certain genes shown to be amplified, including PVT1, can be useful in prediction of poor outcome of patient's response and drug resistance in ovarian cancer patients with low survival rates. Certain genes were found to be high priority therapeutic targets by the identification of recurrent aberrations involving genome sequence, copy number and/or gene expression are associated with reduced survival duration in certain diseases and cancers, specifically ovarian cancer. Therapeutics to inhibit amplification and inhibitors of one of these genes, PVT1, target drug resistance in ovarian cancer patients with low survival rates is described.
Research Organization:
Lawrence Berkeley National Laboratory (LBNL), Berkeley, CA (United States)
Sponsoring Organization:
USDOE
DOE Contract Number:
AC02-05CH11231
Assignee:
The Regents of the University of California (Oakland, CA) ; The Board of Regents, University of Texas System (Austin, TX)
Patent Number(s):
8,404,829
Application Number:
11/814,798
OSTI ID:
1082960
Country of Publication:
United States
Language:
English

References (9)

Prospects for antiviral ribozymes and deoxyribozymes journal January 2004
Gene delivery from polymer scaffolds for tissue engineering journal September 2004
The use of synthetic polymers for delivery of therapeutic antisense oligodeoxynucleotides journal January 2002
Antisense therapeutics: is it as simple as complementary base recognition? journal February 2000
Functional siRNAs and miRNAs Exhibit Strand Bias journal October 2003
Identification of a commonly amplified 4.3 Mb region with overexpression of C8FW, but not MYC in MYC-containing double minutes in myeloid malignancies journal May 2004
Effects of translocations on transcription from PVT. journal April 1990
Nucleic-acid therapeutics: basic principles and recent applications journal July 2002
Progress in Antisense Technology journal February 2004

Similar Records

Amplification of PVT1 contributes to the pathophysiology ofovarian and breast cancer
Journal Article · Tue Oct 09 00:00:00 EDT 2007 · Clinical Cancer Research · OSTI ID:918822
Isoprenylcysteine carboxylmethyltransferase regulates ovarian cancer cell response to chemotherapy and Ras activation
Journal Article · Fri Jun 15 00:00:00 EDT 2018 · Biochemical and Biophysical Research Communications · OSTI ID:23137043
Annexin A9 (ANXA9) biomarker and therapeutic target in epithelial cancer
Patent · Tue Jun 12 00:00:00 EDT 2012 · OSTI ID:1055690

Related Subjects

60 APPLIED LIFE SCIENCES